BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31640478)

  • 1. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor.
    Adams DF; Watkins MS; Durette L; Laliberté J; Goulet F; Debien E; Frazier KS; Mellal N; Chen L; Shi W; Thomas R; Hu E
    Toxicol Pathol; 2020 Feb; 48(2):362-378. PubMed ID: 31640478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
    Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
    J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
    Beck J; Henschel C; Chou J; Lin A; Del Balzo U
    Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
    Holdstock L; Meadowcroft AM; Maier R; Johnson BM; Jones D; Rastogi A; Zeig S; Lepore JJ; Cobitz AR
    J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
    Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
    BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects.
    Hara K; Takahashi N; Wakamatsu A; Caltabiano S
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):410-8. PubMed ID: 26643993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Carcinogenic Potential of Enarodustat (JTZ-951), a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in 26-Week Tg.rasH2 Mouse Study and 2-Year Sprague-Dawley Rat Study.
    Kemmochi Y; Toyoda K; Ishida T; Yasui Y; Shoda T
    Int J Toxicol; 2023 Dec; 42(6):489-503. PubMed ID: 37480334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury.
    Billin AN; Honeycutt SE; McDougal AV; Kerr JP; Chen Z; Freudenberg JM; Rajpal DK; Luo G; Kramer HF; Geske RS; Fang F; Yao B; Clark RV; Lepore J; Cobitz A; Miller R; Nosaka K; Hinken AC; Russell AJ
    Skelet Muscle; 2018 Nov; 8(1):35. PubMed ID: 30424786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
    Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A
    Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daprodustat: First Approval.
    Dhillon S
    Drugs; 2020 Sep; 80(14):1491-1497. PubMed ID: 32880805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.
    Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
    J Pharm Biomed Anal; 2023 Oct; 235():115600. PubMed ID: 37516063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination.
    Mahar KM; Caltabiano S; Andrews S; Ramanjineyulu B; Chen L; Young G; Pereira A; Lindsay AC; van den Berg F; Cobitz AR
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1419-1431. PubMed ID: 34713596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA
    Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents.
    Kowalski H; Hoivik D; Rabinowitz M
    Toxicol Pathol; 2023 Jan; 51(1-2):56-60. PubMed ID: 37158494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.
    Philip M; Karakka Kal AK; Subhahar MB; Karatt TK; Mathew B; Perwad Z
    Drug Test Anal; 2022 Feb; 14(2):317-348. PubMed ID: 34714596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat.
    Yamada M; Osamura M; Ogura H; Onoue T; Wakamatsu A; Numachi Y; Caltabiano S; Mahar KM
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):978-984. PubMed ID: 32250021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daprodustat prevents cyclosporine-A-mediated anemia and peritubular capillary loss.
    Labes R; Brinkmann L; Kulow VA; Roegner K; Mathia S; Balcerek B; Persson PB; Rosenberger C; Fähling M
    Kidney Int; 2022 Oct; 102(4):750-765. PubMed ID: 35643373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.